Sanofi SA (SNY)

49.13
0.07 0.13
NYSE : Health Care
Prev Close 49.07
Open 49.01
Day Low/High 48.83 / 49.20
52 Wk Low/High 36.81 / 50.24
Volume 5.23M
Avg Volume 1.66M
Exchange NYSE
Shares Outstanding 2.58B
Market Cap 127.03B
EPS 1.80
P/E Ratio 26.43
Div & Yield 1.58 (3.20%)

Latest News

Dow Holds Lower After House Passes Health Care Vote, Crude Falls

Dow Holds Lower After House Passes Health Care Vote, Crude Falls

Stocks move mostly lower on Thursday after the House passes a bill to repeal and replace the Affordable Care Act.

Sarepta Therapeutics May Attract Activist Attention

Sarepta Therapeutics May Attract Activist Attention

Large pharmaceutical companies could be interested in buying the drug company, but even if a deal isn't forthcoming an activist investor could seek to elect directors and make one happen

Sarepta CEO Leaves Along With a Sanofi Director, So Let's Speculate About a Possible Deal

Sarepta CEO Leaves Along With a Sanofi Director, So Let's Speculate About a Possible Deal

Sarepta CEO Ed Kaye said he's stepping down.

Biotech Movers: CEO Exit, Tea Leaf Reading Prompts Surge in Sarepta Shares

Biotech Movers: CEO Exit, Tea Leaf Reading Prompts Surge in Sarepta Shares

Sarepta Therapeutics and Vertex Pharmaceuticals and Endo Pharmaceuticals were among the biotech stock movers Friday morning.

Sarepta CEO Exits Along With a Sanofi Director, So Let's Speculate About a Possible Deal

Sarepta CEO Exits Along With a Sanofi Director, So Let's Speculate About a Possible Deal

The timing of these two departures could be coincidental and mean nothing, or they might signal Sanofi's interest in acquiring Sarepta.

Wingstop, Sanofi, Micron Technology: 'Mad Money' Lightning Round

Wingstop, Sanofi, Micron Technology: 'Mad Money' Lightning Round

Jim Cramer is bullish on Wingstop, Sanofi, Micron Technology and Nisource.

Tax Reform Could Boost U.S. Businesses: Cramer's 'Mad Money' Recap (Wednesday 4/26/17)

Tax Reform Could Boost U.S. Businesses: Cramer's 'Mad Money' Recap (Wednesday 4/26/17)

True driving force behind this market remains earnings, says Jim Cramer, but don't ignore the impact of tax reform -- if it happens.

15 Movie Remakes Coming to the Silver Screen in 2017

15 Movie Remakes Coming to the Silver Screen in 2017

Whether you loved the original or not, these sequels are making their way to a theater near you.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AAN, CR, CVLT, CWCO, GPRK, KMB, MDLZ, MVC, OPB, POL, PW, RMBS, SNY Downgrades: ACOR, AKR, FCCY, NRZ, QGEN, SSY, SWFT, TBBK, WRI Initiations: UA Read on to get TheStreet Quant Ratings' detailed report:

K-Mart to Sell Cheaper EpiPen Alternative

K-Mart to Sell Cheaper EpiPen Alternative

K-Mart will charge cash paying customers $199 for a two-pack vs. Mylan's $643.

New Data Suggest Positive Effects Of Sanofi Genzyme's Aubagio® (teriflunomide) On Cortical Gray Matter Atrophy

New Data Suggest Positive Effects Of Sanofi Genzyme's Aubagio® (teriflunomide) On Cortical Gray Matter Atrophy

Sanofi Genzyme, the specialty care global business unit of Sanofi, announced today that new investigational data evaluating the effect of Aubagio ® (teriflunomide) on cortical gray matter atrophy in patients...

New Investigational Data On Six-Year Efficacy Of Sanofi Genzyme's Lemtrada® (alemtuzumab) In Multiple Sclerosis Patients Who Experienced Relapse Between Treatment Courses To Be Presented At AAN

New Investigational Data On Six-Year Efficacy Of Sanofi Genzyme's Lemtrada® (alemtuzumab) In Multiple Sclerosis Patients Who Experienced Relapse Between Treatment Courses To Be Presented At AAN

Sanofi Genzyme, the specialty care global business unit of Sanofi, announced today positive new six-year investigational data from a post-hoc analysis of the extension study of Lemtrada ® (alemtuzumab) in...

Sanofi And Regeneron Announce FDA Approval Of A New Once-Monthly Dosing Option For Praluent® (alirocumab) Injection

Sanofi And Regeneron Announce FDA Approval Of A New Once-Monthly Dosing Option For Praluent® (alirocumab) Injection

- Monthly dosing schedule now approved in both United States and European Union -

Regeneron And Sanofi Announce FDA Approval Of A New Once-Monthly Dosing Option For Praluent® (alirocumab) Injection

Regeneron And Sanofi Announce FDA Approval Of A New Once-Monthly Dosing Option For Praluent® (alirocumab) Injection

Monthly dosing schedule now approved in both United States and European Union

Can Anything Dent the Fox News Brand?

Can Anything Dent the Fox News Brand?

Two sexual harassment scandals might devastate other brands, but not so with Fox News.

Sanofi Sues Mylan Over EpiPen Practices

Sanofi Sues Mylan Over EpiPen Practices

French multinational pharmaceutical company Sanofi on Monday filed a lawsuit against U.S. company Mylan.

Sanofi Epilepsy Drug Responsible for Birth Defects in 4,100 Children, French Regulator Says

Sanofi Epilepsy Drug Responsible for Birth Defects in 4,100 Children, French Regulator Says

Sanofi's Valproate is manufactured in France.

Gilead, Pfizer, AbbVie Win From Lilly's Loss

Gilead, Pfizer, AbbVie Win From Lilly's Loss

The FDA action was a win for Pfizer because Xeljanz escapes competition for one year or more.

Lilly and Incyte Fall After FDA Rejects Potential Blockbuster for Rheumatoid Arthritis

Lilly and Incyte Fall After FDA Rejects Potential Blockbuster for Rheumatoid Arthritis

Gilead, Pfizer, Abbvie stand to gain from Lilly and Incyte Rheumatoid Arthritis Setback.

Biotech Movers: OncoMed Tanks After Barrage of Bad News, Akorn Rises on Deal Talk

Biotech Movers: OncoMed Tanks After Barrage of Bad News, Akorn Rises on Deal Talk

OncoMed Pharmaceuticals, Geron and Akorn were among the biotech stock movers in premarket trading on Monday.

Medivation Founder Takes Helm at Axovant, Shares Spike

Medivation Founder Takes Helm at Axovant, Shares Spike

David Hung will become Axovant's CEO after completing the $14 billion sale of Medivation to Pfizer.

HSBC Security Downgrades Sanofi

HSBC Security Downgrades Sanofi

The stock was trading slightly lower this afternoon.

Second-Quarter Picks and Pans

Second-Quarter Picks and Pans

Las Vegas Sands and Flexion are in, and the autos are out.

Why AbbVie Will be an Incredible Money-Making Machine in an Overvalued Stock Market

Why AbbVie Will be an Incredible Money-Making Machine in an Overvalued Stock Market

The pharmaceutical giant has an attractive yield supported by double-digit earnings growth.

Sanofi to Pay Nearly $20 Million For Drug Overcharges

Sanofi to Pay Nearly $20 Million For Drug Overcharges

Sanofi admitted to overcharging the VA between 2002 and 2011.

Sanofi to Pay for Drug Overcharges

Sanofi to Pay for Drug Overcharges

Sanofi SA agreed to a U.S. Department of Justice a $19.8 million fine for overcharging the U.S. Department of Veteran Affairs.

Switching To Sanofi's Toujeo® Showed Significant Reductions In Blood Sugar And Significantly Lower Incidence Of Hypoglycemia In A Real-World Observational Study

Switching To Sanofi's Toujeo® Showed Significant Reductions In Blood Sugar And Significantly Lower Incidence Of Hypoglycemia In A Real-World Observational Study

- DELIVER 2 Data Showed Reduction in Hypoglycemic Events Related to Inpatient or Emergency Department Visits -

Roche Wins FDA Backing for New Multiple Sclerosis Therapy, Competition Could Crimp Biogen

Roche Wins FDA Backing for New Multiple Sclerosis Therapy, Competition Could Crimp Biogen

The Roche drug, Ocrevus, secured FDA approval for two forms of multiple sclerosis.